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A B S T R A C T
Background: Nonalcoholic steatohepatitis (NASH) is a chronic, progressive, and severe form of nonalcoholic
fatty liver disease. In FLINT, obeticholic acid (OCA) treatment improved multiple histological NASH features.
The design and endpoints of REGENERATE, an ongoing phase 3 study, further evaluate OCA treatment in pa-
tients with fibrosis due to NASH.
Aims: The Month 18 interim analysis assesses the effect of OCA on liver histology, defined as improvement of
fibrosis by ≥1 stage with no worsening of NASH or resolution of NASH with no worsening of fibrosis. The end-
of-study analyses evaluate the effect of OCA on mortality, liver-related clinical outcomes, and long-term safety.
Methods: REGENERATE is a pivotal, long-term study of ~2400 patients with NASH, including ~2100 patients
with stage 2 or 3 liver fibrosis. Additionally, ~300 patients with stage 1 fibrosis and≥1 accompanying co-
morbidity are included to gather information on the safety of OCA and liver disease progression. Patients are
randomised 1:1:1 to receive placebo or OCA (10 or 25mg). A liver biopsy evaluation occurs at screening, Months
18 and 48, and end of study. The duration of the study is dependent upon accrual of a predetermined number of
clinical outcome events.
Conclusions: REGENERATE is designed in conjunction with regulatory authorities to support regulatory ap-
provals in NASH. This robust phase 3 study assesses the effect of OCA on liver histology as a surrogate for
transplant-free survival and liver-related outcomes, including progression to cirrhosis and mortality, and will
ultimately assess clinical benefit through specific evaluation of these outcomes.
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1. Introduction
1.1. Nonalcoholic steatohepatitis (NASH)
Nonalcoholic fatty liver disease (NAFLD) covers a wide spectrum of
diseases, including NASH, that can progress to advanced fibrosis, cir-
rhosis, hepatic decompensation, hepatocellular carcinoma, and liver-
related death [1]. NASH is a chronic, progressive, and severe form of
NAFLD with non-specific symptomatology [2]. The overall global pre-
valence of NAFLD, as diagnosed by imaging, is 25.2%, and the pre-
valence of NASH ranges between 1.5% and 6.5% [3,4]. It is currently
estimated that NASH will become the leading cause of liver trans-
plantation in the next decade [5]. Of the histological features of NASH,
the strongest predictor of adverse clinical outcomes and liver-related
death is fibrosis [6,7]. Liver-related mortality is driven principally by
the development of cirrhosis, which can lead to clinical decompensa-
tion events, sepsis, and hepatocellular carcinoma [3,4,8]. Prevention of
cirrhosis is therefore a major therapeutic objective in patients with
advanced fibrosis due to NASH. Given the high prevalence and pro-
gressive nature of NASH and the fact that radical lifestyle and dietary
changes are difficult to implement, the development of effective phar-
macological therapies is a top priority.
In conjunction with thought leaders, regulatory authorities are
outlining approvable pathways for NASH treatments, including the
identification of endpoints and patient populations that can be priori-
tised for therapy. The Subpart H pathway in the United States and
conditional approval in Europe describe accelerated drug approval
guidelines based on achieving a histological surrogate endpoint fol-
lowed by confirmation of clinical benefit via the evaluation of rigour-
ously quantitative outcomes [9,10].
The farnesoid X receptor (FXR) is a ligand-activated nuclear re-
ceptor expressed predominantly in the liver and small intestine [11]. In
the liver, FXR is expressed primarily in hepatocytes, Kupffer cells, and
endothelial cells [11,12]. FXR activation has pleiotropic effects on
NASH including increased glucose disposal, even in type 2 diabetic
patients, and decreased lipogenesis along with decreased inflammation
[13]. Together, these reduce fibrosis and complement direct antifibrotic
effects on hepatic stellate cells [11]. Through these effects, FXR hits key
elements of the NASH cascade and has a strong biological rationale for
use.
Obeticholic acid (OCA) is a potent, selective FXR agonist derived
from the primary bile acid chenodeoxycholic acid [14]. The efficacy
and safety of OCA in NASH was studied in FLINT, a phase 2b, 18-
month, placebo-controlled study [15]. Daily OCA 25mg improved fi-
brosis as well as other histological features of the disease, such as he-
patocellular ballooning, steatosis, and lobular inflammation, at a sig-
nificantly higher proportion than placebo [15]. This histological
response was correlated with a greater reduction in serum amino-
transferases [15]. OCA treatment in the FLINT study was generally safe
and well tolerated. Pruritus was the most common treatment-emergent
adverse event (TEAE) and was generally mild to moderate in severity
[15].
These promising results and close collaboration with regulatory
authorities led to the design of REGENERATE, the first phase 3 pivotal
study to evaluate the long-term clinical benefit of OCA treatment for
patients with NASH.
2. Materials and methods
2.1. Study design
REGENERATE (ClinicalTrials.gov, NCT02548351) is a pivotal phase
3, prospective, randomised, double-blind, placebo-controlled, multi-
centre study comparing the clinical benefits of once-daily OCA 10 or
25mg with those of placebo. This study includes approximately 2400
adult patients with non-cirrhotic NASH and evidence of stage 1, 2, or 3
liver fibrosis in up to 400 clinical sites worldwide; the majority of pa-
tients (approximately 2100) are either fibrosis stage 2 or stage 3. This
study is designed to assess liver histology as a surrogate endpoint for
clinical outcomes at Month 18 (interim analysis). Patients are followed
long term for clinical outcomes (as a composite of endpoints reflective
of liver failure). According to accelerated approval guidelines, the
planned histological interim analysis is designed to provide a marketing
application to regulatory authorities. The study remains blinded and
ongoing until a sufficient number of clinical outcomes are achieved
(Fig. 1).
2.2. Endpoint rationale
Because of the slow rate of progression in NASH, assessing hard
clinical endpoints is a long-term endeavor. For this reason and because
of the significant healthcare burden, the Food and Drug Administration
(FDA) and European Medicines Agency have described an expedited
approval pathway using a surrogate endpoint to predict clinical benefit
[9,10,16]. For a surrogate endpoint to be clinically meaningful, it must
measure how a patient feels, functions, or survives [17]. Previous
analyses have shown that fibrosis and definite NASH are strongly cor-
related with liver-related mortality and transplant-free survival and
could therefore be used as a histology-based surrogate endpoint [6,7].
Under Subpart H, accelerated pathway for the conditional approval of
non-cirrhotic NASH in phase 3 clinical trials, these surrogate endpoints
are defined as a complete resolution of NASH with no worsening of
fibrosis and/or≥ 1-point improvement in fibrosis with no worsening of
NASH [16,18].
Conditional approval of the previously mentioned endpoints must
be followed by an outcomes study to confirm clinical benefit [10].
Clinical benefit is defined as showing superiority over placebo in de-
laying disease progression as evaluated by progression to cirrhosis,
Fig. 1. REGENERATE study design.
Abbreviations: EOS, end of study; OCA, obeticholic
acid
▲ Biopsy (patients without a liver biopsy performed
within 6months before Day 1 will have a biopsy at
the second Screening Visit).
† Number of adjudicated events accrued in placebo
and OCA 25mg groups combined.
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reduction in hepatic decompensation events, change in model for end-
stage liver disease (MELD) score from ≤12 to> 15, liver transplanta-
tion, or all-cause mortality [9,10].
The design of the REGENERATE phase 3 study originated from the
FDA–American Association for the Study of Liver Diseases workshop
report in 2015; with close collaboration with regulatory authorities, it
has helped define these approval pathways. Both the histology-based
surrogate endpoints being evaluated with the Month 18 interim ana-
lysis and the end-of-study clinical outcomes align with these re-
commendations.
2.3. Dosing rationale
Dosing was selected on the basis of results from the preceding FLINT
trial, which demonstrated the efficacy of OCA 25mg over placebo in
improving measures of steatosis and fibrosis [15]. Although the 25-mg
dose of OCA was generally safe and well tolerated, a higher incidence of
mild to moderate pruritus and an increase in low-density lipoprotein
cholesterol (LDLc) was observed in OCA-treated patients compared
with placebo-treated patients [15]. In a phase 1 trial, OCA 10mg
showed robust FXR activation that was similar to that of OCA 25mg in
patients with NASH Child-Pugh A [19]. Therefore, to mitigate the in-
cidence of pruritus, but maintain similar efficacy, once-daily OCA
10mg is also included in this study.
2.4. Study objectives
The primary objective of the Month 18 interim analysis is im-
provement in fibrosis (reduction of ≥1 stage) with no worsening of
NASH (no worsening of hepatocellular ballooning, lobular inflamma-
tion, or steatosis) or resolution of NASH defined as “no fatty liver dis-
ease” or “fatty liver disease without steatohepatitis” and a histological
score of 0 for ballooning and 0–1 for inflammation with no worsening
of fibrosis as determined by liver biopsy with OCA treatment compared
with placebo. For the end-of-study assessments, clinical benefit is
confirmed by evaluating a composite endpoint defined as the time to
first occurrence of any of the following adjudicated events: death (all-
cause); liver transplantation; a MELD score≥ 15; hospitalisation for
variceal bleed, hepatic encephalopathy, or spontaneous bacterial peri-
tonitis; ascites secondary to cirrhosis; or histological progression to
cirrhosis (Table 1) [20]. Secondary objectives, including additional
histology assessments and liver biochemistry for both the Month 18
interim (histology) and end-of-study (clinical outcomes) analyses, are
also included in Table 1. Exploratory objectives, including patient-re-
ported outcomes, noninvasive measures of liver fibrosis, markers of
inflammation, glucose metabolism, apoptosis, and cardiovascular safety
(including core major adverse cardiovascular events [MACE] and ex-
panded MACE), for both the Month 18 interim and end-of-study ana-
lyses are outlined in Tables A.1 and A.2.
2.5. Study duration
A planned interim analysis occurs after a minimum of 750 patients
complete 18months of treatment. This duration is based on the his-
tology-related changes observed in FLINT, which demonstrated that
OCA improved the histological features of NASH as well as fibrosis after
72 weeks of treatment [15].
The overall study duration is event driven and is determined by the
time required to achieve a sufficient number of adjudicated events in
the OCA 25mg and placebo groups in patients with fibrosis stage 2 or 3.
Although disease progression can be highly variable, this is projected to
be approximately 7 years, with a minimum follow-up of approximately
4 years.
2.6. Sample size justification and statistical considerations
The estimated overall study sample size is based on the clinical
outcomes endpoint analysis at the end of the study. According to the
limited literature available on the natural history of NASH, a placebo
event rate of 20% over 4 years is assumed [21–24]. With this assump-
tion, approximately 2100 patients with fibrosis stage 2 or 3 are ran-
domised in a 1:1:1 ratio to placebo, OCA 10mg, or OCA 25mg to accrue
the required 291 clinical outcomes (OCA 25mg+placebo groups) for
80% power. The assumption is that at least that number of events will
also occur in the OCA 10mg+placebo groups. Randomisation is
stratified by type 2 diabetes at enrolment and use of thiazolidinediones
(TZDs)/glitazones or vitamin E at baseline. An exploratory cohort of
fibrosis stage 1 patients is also enroled, leading to an overall study size
of approximately 2400 patients. These patients do not contribute to the
Subpart H approval endpoint.
Each OCA treatment group is tested against placebo using a log-rank
test stratified by presence of type 2 diabetes at enrolment and use of
TZDs/glitazones or vitamin E at baseline. The alpha will be split be-
tween the Month 18 interim analysis and the end-of-study analysis for a
total overall study alpha of 0.05.
The planned Month 18 interim analysis is performed when a
minimum of 750 randomised patients (the first sequential) with fibrosis
stage 2 or 3 have/should have reached their actual/planned Month 18
visit. This ensures a minimum power of 90% for both primary end-
points.
The primary endpoints are tested using Cochran–Mantel–Haenszel
tests stratified by (I) presence of type 2 diabetes at enrolment (yes/no)
and (II) use of TZDs/glitazones or vitamin E at baseline (yes/no). To
adjust for multiplicity due to two doses as well as two endpoints, a
truncated Hochberg procedure was used.
For all analyses (Month 18 interim and clinical outcomes at the end
of the study), the two doses are tested in a sequential manner with the
OCA 25mg dose tested first. For the Month 18 interim analysis, if both
primary efficacy endpoints are rejected at 25mg, the primary endpoints
will be tested in a similar manner for the 10mg dose. The primary ef-
ficacy population for analysis is the intent-to-treat population with fi-
brosis stage 2 or 3 patients.
3. Study procedures
3.1. Eligibility
Patients aged 18 years or older with definite steatohepatitis, a
nonalcoholic fatty liver disease activity score (NAS)≥ 4, and fibrosis
stage 2 (approximately 40%) or stage 3 (approximately 60%) confirmed
by central reading of a liver biopsy obtained within 6months of ran-
domisation are eligible for the study. To gain further insight into the
population at an earlier stage of NASH, a subgroup of patients with
steatohepatitis and mild fibrosis (stage 1) who are also considered at
high risk of disease progression because of ≥1 accompanying co-
morbidity (obesity, type 2 diabetes, or alanine aminotransferase> 1.5
times the upper limit of normal) is included for an expanded safety
database analysis. Patients were not included if they currently or have a
history of significant alcohol consumption (> 2 units per day for fe-
males and 4 units per day for males for ≥3months) or any other
documented causes of chronic liver disease. If providing a historical
biopsy, they also need to be in a stable metabolic condition, defined as
having a stable body weight (no weight change>10% for ≥3months)
and not taking or on stable doses of TZDs/glitazones or vitamin E for
6months. Additional key inclusion and exclusion criteria are listed in
Table 2.
3.2. Study blinding
During the entire conduct of the study, patients, investigators, and
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the sponsor are blinded to individual treatment assignments. If neces-
sary to ensure safety throughout the study, the data monitoring com-
mittee will have access to unblinded individual patient data. To
maintain the integrity of the final post–Month 18 analysis, only a
minimal number of personnel are unblinded to the patient-level data,
primarily to facilitate regulatory filings and required public disclosures.
3.3. Histological grading
The pathologists are highly qualified and follow a standardised
criterion to ensure consistency between histology readings. All biopsy
specimens are read centrally, including biopsies to determine study
eligibility (collected within 6months of screening), scheduled biopsies
(Month 18, Month 48, and end of study), unscheduled biopsies, and
biopsies performed to confirm suspected cirrhosis. At Month 18 or early
termination, biopsy slides are pair-read with the screening biopsy in a
blinded fashion, ensuring that pathologists are blinded to biopsy se-
quence. Fibrosis staging and the key features of NASH, including stea-
tosis, lobular inflammation, and hepatocellular ballooning, are graded
according to the NASH Clinical Research Network criteria for scoring
[15,26].
3.4. Safety monitoring and assessments
Because of the progressive nature of NASH, the MELD scores are
reviewed by the clinician at each visit to ensure early identification of
disease progression to cirrhosis or decompensation (Fig. A.1). To de-
termine the tolerability of a long-term OCA treatment regimen, TEAEs,
vital signs, electrocardiograms, adjudicated cardiovascular events
(MACE and expanded MACE), and clinical laboratory assessments (in-
cluding lipid profile changes) are evaluated at Month 18 and at the end
of the study [20].
Table 1
Primary and secondary objectives with corresponding assessments.
Month 18 interim analyses (All patients)
Primary objectives Assessment (Based on liver biopsy using NASH CRN criteria)
Improvement in fibrosis with no worsening of
NASH
A≥1-stage reduction in fibrosis and no increase in hepatocellular ballooning, lobular inflammation, or steatosis from baseline
Resolution of NASH with no worsening of
fibrosis
NASH resolution defined as the overall histopathologic interpretation of I) “no fatty liver disease” or II) “fatty liver disease
(simple or isolated steatosis) without steatohepatitis” AND a NAS of 0 for ballooning and 0–1 for inflammation with no
increase in fibrosis stage from baseline
End-of-Study analyses (All patients)
Primary objective Assessment
Clinical outcomes composite endpoint Time to first occurrence of any of the following adjudicated events:
1. Death (all cause);
2. MELD score≥ 15;
3. Liver transplantation;
4. Hospitalisationa for onset of variceal bleed, hepatic encephalopathy,b spontaneous bacterial peritonitisc;
5. Ascites secondary to cirrhosis and requiring medical intervention (e.g. diuretics or paracentesis);
6. Histological progression to cirrhosis
Month 18 interim analyses and End-of-Study analyses (All patients)
Secondary objectives Assessment (Based on liver biopsy using NASH CRN criteria)
≥1-stage reduction in fibrosis AND/OR resolution of NASH, without
worsening of either
Please see definitions above
No worsening of fibrosis AND no worsening of NASH No increase from baseline in fibrosis stage AND no increase in hepatocellular ballooning, lobular
inflammation, or steatosis
Improvement in each key histological feature of NASH A≥1-score reduction from baseline for steatosis, lobular inflammation, or hepatocellular
ballooning
≥2-stage improvement in fibrosis A≥ 2-stage reduction in fibrosis from baseline at Month 18
≥2-point improvement in NAS with no worsening of fibrosis A≥ 2-point reduction in NAS with no increase in fibrosis stage from baseline
Improvement of fibrosis and resolution of NASH as a composite endpoint
(both endpoints being met in the same patient)
A reduction in fibrosis stage ≥1 and a reduction in NAS ≥2 points with ≥1-point improvement
each for hepatocellular ballooning and lobular inflammation from baseline
Resolution of fibrosis (fibrosis stage 0) A fibrosis stage of 0
Liver biochemistry and markers of liver function ALT, AST, GGT, ALP, total and direct bilirubin, albumin, INR, and platelets
Secondary objective: month 18 interim analysis only
Histological progression to cirrhosis A fibrosis stage of 4
Secondary objective: End-of-Study analysis only
Improvement in fibrosis with no worsening of NASH A≥1-stage reduction in fibrosis and no increase in hepatocellular ballooning, lobular
inflammation, or steatosis from baseline
Resolution of NASH with no worsening of fibrosis NASH resolution defined as the overall histopathologic interpretation of I) “no fatty liver disease” or
II) “fatty liver disease (simple or isolated steatosis) without steatohepatitis” AND a NAS of 0 for
ballooning and 0–1 for inflammation with no increase in fibrosis stage from baseline
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRN, clinical research network; GGT, gamma-glutamyl
transferase; INR, international normalised ratio; MELD, model for end-stage liver disease scoring system; NAS, nonalcoholic fatty liver disease activity score; NASH,
nonalcoholic steatohepatitis.
a As defined by a stay of ≥24 h.
b As defined by a West Haven score of ≥2.
c Confirmed diagnostic paracentesis.
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All suspected liver-related clinical outcomes are adjudicated by a
blinded hepatic outcomes committee composed of experts who are not
involved in the study as investigators, data monitoring committee
members, or consultants. Similarly, cardiovascular events are ad-
judicated by an independent committee in accordance with the stan-
dardised definitions for cardiovascular endpoints in clinical trials [27].
Adjudicated events are analysed for core MACE (comprising cardio-
vascular death, non-fatal myocardial infarction, and non-fatal stroke) as
well as expanded MACE (transient ischaemic attack, coronary or per-
ipheral revascularisation procedures, and hospitalisation for congestive
heart failure or unstable angina). MACE are assessed as an exploratory
objective at the Month 18 interim analysis and the end of the study.
Hepatic events are assessed at the end of the study only.
Given the prevalence of dyslipidaemia in patients with NASH and
the potential increase in LDLc with OCA treatment, investigators are
closely monitoring and managing lipid levels. Following a≥15% in-
crease in LDLc from baseline, investigators further assess other cardi-
ovascular risk factors, the risk-benefit of statins or other appropriate
therapy, and other factors relevant for dyslipidaemia management. As
the investigator deems appropriate, statins are initiated or up-titrated, a
regimen that mitigated OCA-induced increases in LDLc in a phase 2
clinical study [28] (Fig. A.2).
3.5. Human studies and patients
This study is in full compliance with the International Council for
Harmonisation Guidance on General Considerations for Clinical Trials
and has been approved by the institutional review board and in-
dependent ethics committee at all study sites. Prior to participation, all
patients provided written informed consent in accordance with the
Declaration of Helsinki, the United States Code of Federal Regulations,
and Good Clinical Practice guidelines.
4. Discussion
REGENERATE initiated patient enrolment in September 2015 to
evaluate histological outcomes and hepatic and metabolic parameters
in patients with advanced fibrosis due to NASH treated with placebo,
OCA 10mg, or OCA 25mg. Upon completion, approximately 2400
patients with liver fibrosis will have been enroled across approximately
400 clinical sites worldwide; however, given the limited information on
the natural history of NASH during the design of the study and the
difficulties in characterising targets for an evolving therapeutic area,
the sample size may be too conservative.
The primary objectives of this study focus on the most recent re-
commended guidelines for phase 3 endpoints for biopsy-based non-
cirrhotic NASH (Table 1) and≥1-point improvement in fibrosis with
no worsening of NASH or the resolution of NASH on overall histo-
pathologic interpretation by an experienced pathologist with no wor-
sening of fibrosis followed by a long-term assessment of clinical benefit
[9,10,16]. Liver-related outcomes are driven by worsening of fibrosis
and development of cirrhosis. As one of the leading drivers of fibrosis,
NASH contributes to these outcomes. Therefore, resolution of NASH as
the primary disease, in theory, should prevent progression to cirrhosis.
Current phase 3 trials are testing the hypothesis that short-term im-
provements in either of these parameters will translate into a reduced
rate of liver-related outcomes. This will help support the transition
towards general acceptance of NASH resolution and fibrosis improve-
ment as surrogate endpoints.
The study design of REGENERATE will provide scientific and
medical insights into the histopathology of long-term effects of OCA
treatment on NASH. Patients in REGENERATE will receive 18months of
OCA prior to interim analyses and subsequent long-term assessments.
Based on results from the FLINT study, a histology assessment following
18months of OCA treatment should be sufficient to observe effects on
features of NASH as well as fibrosis. Although lengthy treatments in
clinical trials can be logistically challenging, the approximately 7-year
treatment period in REGENERATE will allow for robust investigation
into the safety and therapeutic potential of OCA and also provide in-
sight into the natural history of advanced disease in NASH.
The results from REGENERATE may also confirm additional clinical
benefits by accelerating innovations in the use of bile acid modulators
for various liver-related conditions. REGENERATE will provide addi-
tional, clinically meaningful outcomes by evaluating OCA treatment in
patients with varying disease states, including those with advanced
disease who are at a high risk of disease progression. This will help to
capture the effects of OCA in patients with NASH who have the greatest
unmet clinical needs. The enrolment criteria implemented in this trial
(Table 2) maximise the likelihood of assessing outcomes that confirm
the clinical benefits of OCA.
The optimal trial duration for assessing benefits on steatohepatitis
and fibrosis stage is currently unsettled but most likely depends on the
study drug's mechanism of action and study endpoint(s). A previous
study demonstrated effects of pioglitazone on inflammation and liver
cell injury in steatohepatitis in as little as 6months; another study
confirmed fibrosis reduction after only 6months of treatment [29,30].
However, the small sample size of these studies may correspond to a
high risk of alpha-type error. Other studies have shown the antifibrotic
effects of cenicriviroc and elafibranor after 12months of treatment, but
the antifibrotic effects of elafibranor were apparent only in patients
who cleared NASH (i.e. responders for NASH resolution, defined as the
disappearance of ballooning together with either disappearance of
lobular inflammation or persistence of mild lobular inflammation only)
[31,32]. Therefore, depending on the mechanism of action, the time
necessary to capture the full antifibrotic effect may be variable, and
Table 2
REGENERATE Key inclusion and exclusion criteria [25].
Key inclusion criteria Key exclusion criteria
Histological evidence of NASHa Histological presence of cirrhosis
Age ≥18 years HbA1c > 9.5% ≤60 days before Day 1
Stable body weight (≤10% variation
for ≥3months before Day 1)
Prior exposure to OCA
History of biliary diversion
Stable dose of vitamin E or TZD Significant alcohol consumptionb
Histological evidence of fibrosis
assessed by NASH CRN scoring
system:
1. Stages 2–3 (primary efficacy
analysis)
2. Stages 1a-1b if accompanied by
≥1 of the following:
1. Obesity (BMI ≥30 kg/m2)
2. Type 2 diabetesc
3. Elevated ALT (> 1.5xULN)
Prior or planned ileal resection
Bariatric surgery within 5 years
MELD score > 12
Other causes of concomitant liver disease
and history of liver transplantation
Total bilirubin > 1.5mg/dL
Conjugated bilirubin ≥1.5xULN
AST or ALT ≥10xULN; INR ≥1.4; serum
creatinine ≥1.5mg/dL; creatine
phosphokinase > 5xULN
Platelet count <100,000/mm3
LDL ≥190mg/dL with stable statin use
or PCSK9 inhibitor ≥30 days prior to
screening
Acute cholecystitis or biliary obstruction
Abbreviations: ADA, American Diabetes Association; ALT, alanine amino-
transferase; AST, aspartate aminotransferase; BMI, body mass index; CRN,
clinical research network; HbA1c, hemoglobin A1c; INR, international nor-
malised ratio; LDL, low-density lipoprotein; MELD, model for end-stage liver
disease scoring system; NASH, nonalcoholic steatohepatitis; OCA, obeticholic
acid; PCSK9, proprotein convertase subtilisin/kexin type 9; TZD, thiazolidine-
dione; ULN, upper limit of normal.
a Biopsy obtained ≤6months before Day 1 defined by the presence of all 3
key histological features of NASH (steatosis, ballooning degeneration, and
lobular inflammation) with a score of ≥1 for each histological feature and a
combined score≥ 4 according to the NASH CRN criteria [26].
b Defined as>2 units per day for females and > 4 units per day for males,
on average.
c Diagnosed per 2013 ADA criteria (HbA1c ≥6.5%, fasting plasma glucose
≥126mg/dL, 2-h plasma glucose ≥200mg/dL during oral glucose tolerance
test, or random plasma glucose≥200mg/dL).
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longer treatment durations may allow both direct and indirect (sub-
sequent to the clearance of steatohepatitis) antifibrotic effects to be-
come visible. The FLINT trial, which was conducted over 18months,
demonstrated an improvement in all histological parameters including
fibrosis; therefore, an 18-month period was chosen as a conservative
assumption in REGENERATE.
Although liver biopsies remain the gold reference standard in NASH
trials, there is a need for a reliable NASH biomarker that accurately
identifies NASH features and correlates with steatohepatitis over time.
The study design of REGENERATE includes exploratory endpoints such
as non-invasive assessments, which have the potential for use as NASH
biomarkers in future trials (Tables A.1 and A.2).
As the clinical landscape continues to evolve and regulatory path-
ways are put into place, the robustness of the REGENERATE study
provides critical insights on how to study NASH and the disease state.
5. Conclusions
REGENERATE is a pivotal phase 3 study designed in close colla-
boration with regulatory authorities to evaluate short-term and long-
term effects of OCA on liver histology and on progression to cirrhosis,
liver-related clinical outcomes, and mortality. It assesses predictors of
histological response as well as the interaction between histological
improvement and liver biochemical and metabolic effects. In addition,
this study provides key data on the natural history of NASH owing to
the systematic, protocol-based assessment of histological progression
over several years in the placebo group, as well as the role of the FXR
pathway in the treatment of NASH. Therefore, REGENERATE should
provide valuable information for the development of future NASH trials
and for scientific justification of the regulatory approval process
(ClinicalTrials.gov, NCT02548351).
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